HUP0105070A2 - Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet - Google Patents

Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet

Info

Publication number: HUP0105070A2
Authority: HU; Hungary
Prior art keywords: hepatitis; treatment; prevention; antiviral agent; novel treatment
Prior art date: 1999-01-12

Application number

HU0105070A

Other languages

English (en)

Hungarian (hu)

Inventor

Gillian Frances Atkinson

Ronald James Boon

Pierre G. Vandepapeliere

Martine Anne Cecile Wettendorff

Original Assignee

Smithkline Beecham Biologicals S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-12

Filing date

1999-12-21

Publication date

2002-04-29

1999-12-21 Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.

2002-04-29 Publication of HUP0105070A2 publication Critical patent/HUP0105070A2/hu

Links

208000002672 hepatitis B Diseases 0.000 abstract 3
239000003443 antiviral agent Substances 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
241000700721 Hepatitis B virus Species 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 abstract 1
229940124736 hepatitis-B vaccine Drugs 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HU0105070A 1999-01-12 1999-12-21 Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet HUP0105070A2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9900630		1999-01-12
PCT/EP1999/010295 WO2000041463A2 (fr)	1999-01-12	1999-12-21	Nouveau traitement

Publications (1)

Publication Number	Publication Date
HUP0105070A2 true HUP0105070A2 (hu)	2002-04-29

Family

ID=10845878

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU0105070A HUP0105070A2 (hu)	1999-01-12	1999-12-21	Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet

Country Status (19)

Country	Link
EP (1)	EP1140163A2 (fr)
JP (1)	JP2002534438A (fr)
KR (1)	KR20010090011A (fr)
CN (1)	CN1391482A (fr)
AR (1)	AR022250A1 (fr)
AU (1)	AU760574B2 (fr)
BR (1)	BR9916893A (fr)
CA (1)	CA2359110A1 (fr)
CO (1)	CO5241355A1 (fr)
CZ (1)	CZ20012544A3 (fr)
HK (1)	HK1041434A1 (fr)
HU (1)	HUP0105070A2 (fr)
IL (1)	IL144186A0 (fr)
NO (1)	NO20013337L (fr)
NZ (1)	NZ512890A (fr)
PL (1)	PL349347A1 (fr)
TR (1)	TR200102024T2 (fr)
WO (1)	WO2000041463A2 (fr)
ZA (1)	ZA200105690B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999061056A2 (fr)	1998-05-22	1999-12-02	Loeb Health Research Institute At The Ottawa Hospital	Methodes et produits permettant d'induire une immunite au niveau des muqueuses
CN1560078B (zh)	1998-07-31	2011-06-22	株式会社国际癌症免疫研究所	基于癌抑制基因wt1的产物的癌抗原
CA2440303C (fr)	2001-03-22	2013-03-19	Haruo Sugiyama	Peptide modifie wt1
US8735357B2 (en)	2001-09-28	2014-05-27	International Institute Of Cancer Immunology, Inc.	Method of inducing antigen-specific T cells
JPWO2003028758A1 (ja) *	2001-09-28	2005-01-13	治夫杉山	抗原特異的ｔ細胞の誘導方法
MY131488A (en) *	2002-04-08	2007-08-30	Bristol Myers Squibb Co	Low dose liquid entecavir formulations and use
PT2241325E (pt)	2002-10-29	2012-04-12	Coley Pharm Gmbh	Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
AU2003300919A1 (en)	2002-12-11	2004-06-30	Coley Pharmaceutical Gmbh	5' cpg nucleic acids and methods of use
CN100443117C (zh) *	2003-05-13	2008-12-17	深圳康泰生物制品股份有限公司	一种治疗性乙型肝炎的疫苗制剂、其制备方法及其用途
US8541167B2 (en)	2004-06-03	2013-09-24	Saint Louis University	Methods and compositions for vaccination
AR065504A1 (es) *	2007-02-28	2009-06-10	Ct Ingenieria Genetica Biotech	Terapia combinada para el tratamiento de la hepatitis b cronica. uso.
WO2020134682A1 (fr) *	2018-12-24	2020-07-02	南京远大赛威信生物医药有限公司	Préparation pharmaceutique pour le traitement de l'hépatite b, procédé de préparation s'y rapportant et utilisation associée
EP4321173A1 (fr) *	2021-04-07	2024-02-14	Denka Company Limited	Activateur d'activité d'adjuvant et composition d'adjuvant

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2109921T3 (es) *	1989-07-25	1998-02-01	Smithkline Beecham Biolog	Nuevos antigenos y procedimientos para su preparacion.
EP1064025B1 (fr) *	1998-03-09	2006-09-13	GlaxoSmithKline Biologicals S.A.	Compositions de vaccins combines

1999
- 1999-12-21 PL PL99349347A patent/PL349347A1/xx not_active Application Discontinuation
- 1999-12-21 KR KR1020017008833A patent/KR20010090011A/ko not_active Application Discontinuation
- 1999-12-21 CN CN99816471A patent/CN1391482A/zh active Pending
- 1999-12-21 CZ CZ20012544A patent/CZ20012544A3/cs unknown
- 1999-12-21 AU AU21009/00A patent/AU760574B2/en not_active Ceased
- 1999-12-21 TR TR2001/02024T patent/TR200102024T2/xx unknown
- 1999-12-21 EP EP99965531A patent/EP1140163A2/fr not_active Withdrawn
- 1999-12-21 HU HU0105070A patent/HUP0105070A2/hu unknown
- 1999-12-21 IL IL14418699A patent/IL144186A0/xx unknown
- 1999-12-21 JP JP2000593088A patent/JP2002534438A/ja active Pending
- 1999-12-21 WO PCT/EP1999/010295 patent/WO2000041463A2/fr not_active Application Discontinuation
- 1999-12-21 CA CA002359110A patent/CA2359110A1/fr not_active Abandoned
- 1999-12-21 BR BR9916893-6A patent/BR9916893A/pt not_active IP Right Cessation
- 1999-12-21 NZ NZ512890A patent/NZ512890A/en unknown
2000
- 2000-01-11 AR ARP000100107A patent/AR022250A1/es not_active Application Discontinuation
- 2000-01-12 CO CO00001261A patent/CO5241355A1/es not_active Application Discontinuation
2001
- 2001-07-05 NO NO20013337A patent/NO20013337L/no not_active Application Discontinuation
- 2001-07-11 ZA ZA200105690A patent/ZA200105690B/xx unknown
2002
- 2002-02-19 HK HK02101211.9A patent/HK1041434A1/zh unknown

Also Published As

Publication number	Publication date
KR20010090011A (ko)	2001-10-17
TR200102024T2 (tr)	2001-12-21
EP1140163A2 (fr)	2001-10-10
CZ20012544A3 (cs)	2002-01-16
AR022250A1 (es)	2002-09-04
JP2002534438A (ja)	2002-10-15
HK1041434A1 (zh)	2002-07-12
NO20013337L (no)	2001-08-17
WO2000041463A3 (fr)	2000-11-09
PL349347A1 (en)	2002-07-15
IL144186A0 (en)	2002-05-23
ZA200105690B (en)	2002-09-25
NO20013337D0 (no)	2001-07-05
WO2000041463A2 (fr)	2000-07-20
AU2100900A (en)	2000-08-01
CA2359110A1 (fr)	2000-07-20
CO5241355A1 (es)	2003-01-31
NZ512890A (en)	2003-09-26
BR9916893A (pt)	2001-11-20
AU760574B2 (en)	2003-05-15
CN1391482A (zh)	2003-01-15

Publication	Publication Date	Title
GEP20104960B (en)	2010-04-26	USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
HUP0102441A2 (hu)	2001-10-28	Megváltozott interferon-antagonista aktivitással rendelkező, legyengített negatívszálú vírusok vakcinaként és gyógyszerként való alkalmazásra
HUP0202502A2 (hu)	2002-11-28	Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
HUP0105070A2 (hu)	2002-04-29	Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet
HUP0002224A1 (hu)	2001-04-28	Virusellenes hatású benzimidazol-származékok
BR0111195A (pt)	2004-07-20	Uso de b-l-2'-desoxi-nucleosìdeos no tratamento de infecção por vìrus de hepatite delta
HUP0103319A2 (hu)	2002-05-29	Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk
HUP0400719A2 (hu)	2004-07-28	Vegyületek és eljárások Chlamydia-fertőzés diagnosztikájára és kezelésére
HUP0100100A2 (hu)	2001-11-28	Hepatitis C inhibitor peptid-analógok, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
RS20120201A3 (en)	2013-06-28	METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
TR199802329T2 (xx)	2002-12-23	Enfeksiyon hastal�klar�n�n tedavisinde IL-12 ve IFNalfa kullan�m�.
MY141594A (en)	2010-05-14	3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
ATE327246T1 (de)	2006-06-15	Hepatitis c tripeptid inhibitoren
HUP0104709A2 (hu)	2002-04-29	Eritropoietin vagy eritropoietrinszármazékok alkalmazása agyi iszkémiák kezelésére használható gyógyszer előállítására
BG100455A (en)	1997-09-30	Hiv protease inhibitors
WO2001077091A3 (fr)	2002-03-21	Inhibiteurs de polymerases ns5b vhc
HUP0202570A1 (hu)	2002-11-28	Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
ATE306938T1 (de)	2005-11-15	Verwendung von cpg als adjuvans für hivimpstoff
HUP0402259A2 (hu)	2005-01-28	Vakcinák
HUP0301349A2 (hu)	2003-08-28	IL-11-tartalmú készítmények
ATE486634T1 (de)	2010-11-15	Caspase 3, 8, 9 oder 10 inhibitoren in kombination mit mek inhibitoren zur behandlung von influenza
ATE458496T1 (de)	2010-03-15	Hiv-vakzine und anwendungsverfahren
ATE339211T1 (de)	2006-10-15	L-fmau zur behandlung von hepatitis-delta-virus- infizierung
HUP0200162A2 (hu)	2002-05-29	Haemophilus somnus transzferrin-kötő fehérjék klónozása és expresszálása
WO2004006848A3 (fr)	2004-12-16	Polytherapies avec ftc destinees au traitement d'une infection a virus de l'hepatite b